Bullish indicating open at $55-$60, IPO prices at $37
Scott Dreyer, Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical , Inc. (NASDAQ:COLL), a company with impressive gross margins of 87% and a strong financial health rating according to InvestingPro, sold a total of 2,255 shares of the company’s common stock. The shares were sold at a weighted average price of $30.0049, resulting in a total transaction value of $67,661. Following this sale, Dreyer retains ownership of 124,421 shares in the company. The transaction was conducted as part of a pre-established Rule 10b5-1 trading plan, which Dreyer adopted on August 28, 2024. Trading at a P/E ratio of 13.9 with analyst targets ranging from $36 to $50, InvestingPro analysis suggests the stock is currently undervalued. Get access to 8 more exclusive ProTips and comprehensive research reports for COLL and 1,400+ other stocks with an InvestingPro subscription.
In other recent news, Collegium Pharmaceuticals reported impressive fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $1.75, compared to the forecast of $1.66. The company also exceeded revenue projections, posting $181.9 million against the anticipated $179.48 million. This strong performance was driven by robust growth in the ADHD and pain management portfolios, with annual revenue for 2024 reaching $631.4 million, an 11% increase from the previous year. Additionally, Collegium has announced significant changes to its board of directors and executive team, with Gino Santini set to become the new Chairman of the Board, succeeding the retiring Michael Heffernan. Dr. Carlos Paya has been nominated to join the board, bringing extensive experience from the biopharmaceutical sector. On the executive front, David Dieter has been appointed as Executive Vice President and General Counsel, joining the leadership team alongside new executives Jane Gonnerman and Dean J. Patras. These developments are part of Collegium’s strategy for board refreshment and succession planning. The company has also projected positive guidance for 2025, with expected revenue and EBITDA growth, reflecting confidence in its strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.